Etoricoxib Allergy Manifestations
Etoricoxib, a selective COX-2 inhibitor, can cause a spectrum of allergic manifestations ranging from mild cutaneous reactions (most commonly urticaria, angioedema, and fixed drug eruptions) to rare but severe reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and anaphylaxis.
Cutaneous Manifestations (Most Common)
The skin is the primary target organ for etoricoxib hypersensitivity reactions:
Urticaria and angioedema: These are the most frequently reported allergic manifestations 12. Symptoms typically develop within 1 hour of drug exposure 2. In patients with cross-intolerant NSAID hypersensitivity who are also intolerant to paracetamol, approximately 25% will react to etoricoxib with urticaria/angioedema 2.
Fixed drug eruption (FDE): This is a characteristic pattern where isolated or multiple skin lesions repeatedly appear in the same location after each exposure 3. Etoricoxib-induced FDE presents as well-demarcated, hyperpigmented patches that recur at identical sites with re-exposure. Diagnosis can be confirmed by positive lesional patch testing 3.
Rash: Non-specific rashes occur in 1-3% of patients, including erythematous and maculopapular variants 1. Pruritus may accompany these eruptions 1.
Erythema multiforme-like eruptions: Target-like lesions resembling erythema multiforme have been documented 4.
Mucosal Reactions
Mucosal involvement can occur as a selective reaction to etoricoxib:
- Stomatitis with mucosal exfoliation 5
- Oral erosions and tongue angioedema 5
- Vaginal burning and mucosal irritation 5
These mucosal reactions are particularly notable as they can occur even in patients who tolerate non-selective NSAIDs, indicating true selective hypersensitivity to COX-2 inhibitors 5.
Severe Cutaneous Adverse Reactions (Rare but Life-Threatening)
Although etoricoxib was developed with an improved safety profile, severe reactions do occur:
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): While the incidence is low 1, fatal cases have been reported 6. These manifest as widespread epidermal detachment, mucosal involvement, and systemic toxicity. Immediate discontinuation is mandatory if any bullous or exfoliative skin rash develops 1.
Patients should be instructed to stop the drug immediately if they develop any type of rash, blisters, fever, or signs of hypersensitivity 1.
Systemic Hypersensitivity Reactions
Anaphylaxis and anaphylactoid reactions can occur, presenting with:
These require immediate emergency intervention 1.
Respiratory Manifestations
Importantly, reactions to selective COX-2 inhibitors are extremely rare in patients with aspirin-exacerbated respiratory disease (AERD), and these agents can typically be taken safely in this population 7. This distinguishes etoricoxib from non-selective NSAIDs, which reliably trigger respiratory reactions in AERD patients.
Clinical Patterns and Cross-Reactivity
The evidence reveals important patterns:
Selective hypersensitivity: Some patients demonstrate true selective hypersensitivity to etoricoxib while tolerating non-selective NSAIDs 5, indicating drug-specific rather than class-wide reactions.
Cross-intolerance patterns: In patients with cross-intolerant NSAID hypersensitivity (reacting to multiple structurally unrelated NSAIDs), tolerance to etoricoxib varies based on paracetamol tolerance. Those intolerant to paracetamol have a 25% risk of reacting to etoricoxib, while those tolerant to paracetamol have only a 6% risk 2.
Key Clinical Pitfalls
Don't assume COX-2 selectivity guarantees safety: While reactions are less common than with non-selective NSAIDs, they still occur in 1.4-25% of patients depending on their hypersensitivity phenotype 28.
Timing matters: Most reactions occur within 1 hour of exposure 2, but delayed reactions (FDE) can occur with repeated exposures 3.
Severity can escalate: Initial mild reactions don't preclude severe reactions upon re-exposure 6.
Diagnostic Confirmation
When etoricoxib allergy is suspected: